Purpose: Serotonin is biochemically present in the iris and ciliary body of animals and humans. Controversial findings are reported about the concentrations of serotonin in aqueous humor with respect to plasma in humans. The aim of this study was to evaluate the levels of serotonin both in aqueous humor and plasma in human subjects. Methods: In 50 patients with glaucoma or cataract, plasma and aqueous humor serotonin levels were measured by HPLC with electrochemical detection. Serotonin plasma levels were also measured in 25 healthy subjects as controls. Results: In all patients with cataract or glaucoma, the aqueous humor serotonin concentration is significantly lower than that in plasma [1.14±0.29 (SEM) vs. 5.33±1.03 ng/ml, p < 0.01]. Furthermore, in the same patients and in 25 healthy controls, serotonin plasma levels were similar. Conclusion: Our study shows that serotonin is present in human aqueous humor and its concentration is 4 times lower than in plasma.

1.
Fozard JR: Actions of 5-hydroxytryptamine; in Fozard JR, (ed): The peripheral actions of 5-hydroxytryptamine. Oxford Medical Publications. Oxford, Oxford University Press, 1989, pp I–410.
2.
Klyce SD, Palkama KA, Marshall WS, Huhtaniitty S, Mann KP: Evidence for serotonergic receptors in corneal epithelium. Invest Ophthalmol Vis Sci 1981;20:194.
3.
Klyce SD, Palkama KA, Harkonen M, Marshall WS, Huhtaniitty S, Mann KP: Neural serotonin stimulates chloride transport in rabbit corneal epithelium. Invest Ophthalmol Vis Sci 1982;23:193–198.
4.
Osborne NN: The occurrence of serotonergic nerves in bovine cornea. Neurosci Lett 1983;35:15–18.
5.
Osborne NN; Tobin AB: Serotonin-accumulating cells in the iris-ciliary body and cornea of various species. Exp Eye Res 1987;44:731–746.
6.
Trope GE, Sole M, Aedy L, Madapallimattam A: Levels of norepinephrine, epinephrine, dopamine, serotonin and N-acetylserotonin in aqueous humour. Can J Ophthalmol 1987;22:152–154.
7.
Martin XD, Brennan MC, Lichter PR: Serotonin in human aqueous humor. Ophthalmology 1988;95:1221–1226.
8.
Uusitalo H, Lehtosalo J, Laakso J, Harkonen M, Palkama KA: Immunohistochemical and biochemical evidence for 5-hydroxytryptamine containing nerves in the anterior part of the eye. Exp Eye Res 1982;35:671–675.
9.
Ozanics V, Jakobiec FA: Prenatal development of the eye and its adnexa; in Duane TD, Jaeger EA (eds): Biomedical Foundations of Ophthalmology. Philadelphia, Harper & Row, 1986, vol 1, pp 87–96.
10.
Wiechmann AF: Melatonin: Parallels in pineal gland and retina. Exp Eye Res 1986;42:507–527.
11.
Ferrera LA, Fasano ML, Soro S, Pasanisi F, Mancini M: Antihypertensive efficacy of a combination of ketanserin and thiazide in hypertensives older than 50 years. J Cardiovasc Pharmacol 1987;47:689–698.
12.
Riemann IW, Frolich JC: Mechanism of antihypertensive action of ketanserin in man. Br Med J 1983;287:381–383.
13.
Van Nueten JM, Janssen PAJ, van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM: Vascular effects of ketanserin, a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 1981;218:217–230.
14.
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ: Receptor binding profile of R 41468, a novel antagonist of 5-HT receptors. Life Sci 1981;28:1015–1022.
15.
Chang FW, Burke JA, Potter DE: Mechanism of the ocular hypotensive action of ketanserin. J Ocul Pharmacol 1985;1:137–147.
16.
Conway JL, Lewis FA: Ocular hypotensive action of ketanserin. Invest Ophthalmol Vis Sci 1989;suppl 30:24.
17.
Costagliola C, Fasano ML, Iuliano G, Ferrara LA: Effect of ketanserin on intraocular pressure. Cardiovasc Drug Ther 1990;4:95–97.
18.
Costagliola C, Scibelli G, Fasano ML, Ferrara LA, Mastropasqua L: Effect of oral ketanserin administration on intraocular pressure in glaucomatous patients. Exp Eye Res 1990;52:507–510.
19.
Seegal RF, Brosch KO, Bush B: High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. J Chromatogr 1986;377:131–144.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.